AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease
Executive Summary
Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.
You may also be interested in...
Safety Issues Not Dampening AbbVie Optimism For Humira Successors
AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.
AbbVie’s Cancer Expansion Is Paying Off
Label-expansion plans for Imbruvica, along with approvals for Venclexta and Rova-T headline AbbVie's efforts to build a substantial cancer portfolio. The BTK inhibitor was AbbVie's second-best seller in 2016, passing HCV combo Viekira Pak.
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.